mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting

OncoImmunology

Volumn 7, Issue 1, 2018, Pages

  Lohmueller, Jason J ^a   Ham, James D ^a,b   Kvorjak, Michael ^a   Finn, Olivera J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CARNEGIE MELLON UNIVERSITY   (United States)

Author keywords

adoptive cell therapy; cancer immunotherapy; CAR; Chimeric antigen receptor; synthetic biology; tag CAR

Indexed keywords

EID: 85032361775     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1368604     Document Type: Article

References (26)

1. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507-17. https://doi.org/10.1056/NEJMoa1407222. PMID:25317870
2. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86:10024-8. https://doi.org/10.1073/pnas.86.24.10024. PMID:2513569
3. Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388-98. https://doi.org/10.1158/2159-8290.CD-12-0548. PMID:23550147
4. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509-18. https://doi.org/10.1056/NEJMoa1215134. PMID:23527958
5. Park JH, Riviere I, Wang X, Bernal YJ, Yoo S, Purdon T, et al. CD19-Targeted 19–28z CAR Modified Autologous T Cells Induce High Rates of Complete Remission and Durable Responses in Adult Patients with Relapsed, Refractory B-Cell ALL. Blood 2014;124:382.
6. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725-33. https://doi.org/10.1056/NEJMoa1103849. PMID:21830940
7. Lohmueller J, Finn OJ. Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. Pharmacol Ther 2017;pii:S0163-7258(17)30088-8. https://doi.org/10.1016/j.pharmthera.2017.03.008. PMID:28322974
8. Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Perazzelli J, Klichinsky M, Aikawa V, Nazimuddin F, Kozlowski M, et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016;126:3814-26. https://doi.org/10.1172/JCI87366. PMID:27571406
9. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188-95. https://doi.org/10.1182/blood-2014-05-552729. PMID:24876563
10. Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13:394. https://doi.org/10.1038/nrclinonc.2016.65. PMID:27118494
11. Rodgers DT, Mazagova M, Hampton EN, Cao Y, Ramadoss NS, Hardy IR, Schulman A, Du J, Wang F, Singer O, et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci U S A. 2016;113:E459-68. https://doi.org/10.1073/pnas.1524155113. PMID:26759369
12. Tamada K, Geng D, Sakoda Y, Bansal N, Srivastava R, Li Z, Davila E. Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res. 2012;18:6436-45.https://doi.org/10.1158/1078-0432.CCR-12-1449. PMID:23032741
13. Urbanska K, Lanitis E, Poussin M, Lynn RC, Gavin BP, Kelderman S, Yu J, Scholler N, Powell DJ, Jr. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 2012;72:1844-52. https://doi.org/10.1158/0008-5472.CAN-11-3890. PMID:22315351
14. Kudo K, Imai C, Lorenzini P, Kamiya T, Kono K, Davidoff A, Chng WJ, Campana D. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res. 2014;74:93-103. https://doi.org/10.1158/0008-5472.CAN-13-1365. PMID:24197131
15. Urbanska K, Powell DJ. Development of a novel universal immune receptor for antigen targeting: To Infinity and beyond. Oncoimmunology 2012;1:777-9. https://doi.org/10.4161/onci.19730. PMID:22934280
16. Ma JS, Kim JY, Kazane SA, Choi SH, Yun HY, Kim MS, Rodgers DT, Pugh HM, Singer O, Sun SB, et al. Versatile strategy for controlling the specificity and activity of engineered T cells. Proc Natl Acad Sci U S A. 2016;113:E450-8. https://doi.org/10.1073/pnas.1524193113. PMID:26759368
17. Lim KH, Huang H, Pralle A, Park S. Stable, high-affinity streptavidin monomer for protein labeling and monovalent biotin detection. Biotechnol Bioeng. 2013;110:57-67. https://doi.org/10.1002/bit.24605. PMID:22806584
18. Lohmueller JJ, Sato S, Popova L, Chu IM, Tucker MA, Barberena R, Innocenti GM, Cudic M, Ham JD, Cheung WC, et al. Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential. Sci Rep. 2016;6:31740. https://doi.org/10.1038/srep31740. PMID:28442756
19. Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, Wilson WH, Rosenberg SA. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother. 2009;32:689-702. https://doi.org/10.1097/CJI.0b013e3181ac6138. PMID:19561539
20. Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, Quintás-Cardama A, Larson SM, Sadelain M. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2007;13:5426-35. https://doi.org/10.1158/1078-0432.CCR-07-0674. PMID:17855649
21. Campana D, Schwarz H, Imai C. 4-1BB chimeric antigen receptors. Cancer J. 2014;20:134-40. https://doi.org/10.1097/PPO.0000000000000028. PMID:24667959
22. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, Varela-Rohena A, Haines KM, Heitjan DF, Albelda SM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A. 2009;106:3360-5. https://doi.org/10.1073/pnas.0813101106. PMID:19211796
23. Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol. 2004;172:104-13. https://doi.org/10.4049/jimmunol.172.1.104. PMID:14688315
24. Kane LP, Andres PG, Howland KC, Abbas AK, Weiss A. Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-gamma but not TH2 cytokines. Nat Immunol. 2001;2:37-44. https://doi.org/10.1038/83144. PMID:11135576
25. Weir C, Hudson AL, Moon E, Ross A, Alexander M, Peters L, Langova V, Clarke SJ, Pavlakis N, Davey R, et al. Streptavidin: a novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines. Cancer Immunol Res. 2014;2:469-79. https://doi.org/10.1158/2326-6066.CIR-13-0157. PMID:24795359
26. Yumura K, Ui M, Doi H, Hamakubo T, Kodama T, Tsumoto K, Sugiyama A. Mutations for decreasing the immunogenicity and maintaining the function of core streptavidin. Protein Sci. 2013;22:213-21. https://doi.org/10.1002/pro.2203. PMID:23225702